This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

PSA kinetics

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

'PSA kinetics'

  • PSA velocity (PSAv) refers to the absolute rate of PSA change over time

    • evidence has indicated that PSA may need to take into account both age and individual PSA value to optimise interpretation
    • in clinical practice, a minimum of three values is required over at least 18 months for a meaningful assessment
    • may offer prognostic information as to how an individual prostate cancer may behave after diagnosis with a rise in over 2 ng/ml in the year prior to diagnosis predicting a more aggressive disease course or higher post-therapy relapse rate (D'Amico et al. 2005)

  • PSA doubling time (PSAdt)
    • refers to the time taken for a serum PSA value to double and is also emerging as useful pre-treatment marker of a prostate tumour's biological potential (Klotz 2005)
    • calculated PSAdt of less than 3 years may indicate a more aggressive tumour course

References

  • D'Amico AV, Renshaaw AA, Sussman B, Chen MH. Pre-treatment PSA velocity and the risk of death from prostate cancer following external beam radiotherapy. N Eng J Med 2005; 294: 440-7
  • Klotz L.Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16-21
  • NICE (May 2019). Prostate cancer: diagnosis and management

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.